Key Takeaways Teva signed a deal with RPRX for the speedy development of anti-IL-15 antibody TEV-'408 for vitiligo.RPRX will co-fund a phase IIb vitiligo study, with an option to invest in phase III pending results.TEVA keeps rights while paying milestones and royalties if approved, lowering risk via non-dilutive funding.Teva Pharmaceuticals (TEVA) announced a funding agreement with Royalty Pharma plc (RPRX) , under which the latter will provide up to $500 million to accelerate the development of Teva’s ant ...